Director/PCA Dealing and Donation of Shares to Foundation
Founders donate 500,000 shares to Finnish medical research foundation; sell 300,000 shares separately.
- Shares donated to foundation 500,000
- Shares sold 300,000
- Foundation holding after donation 0.45% of voting rights
- Combined holding of Markku and Sirpa Jalkanen after transactions 2.33% of voting rights
Select text to share a quote on X · sign in to keep highlights & notes in your FARN notes
| Faron Pharmaceuticals Ltd | Company announcement | June 05, 2025 at 18:00:00 EEST |
TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces that its founding members Markku Jalkanen, a director of the Company, and his spouse Sirpa Jalkanen have on 3 June 2025 donated 500,000 ordinary shares in the Company to the Finnish Foundation that bears their name (“Sirpa ja Markku Jalkasen Säätiö sr”, Business ID 1729345-2) (the ”Foundation”). Markku Jalkanen donated 400,000 ordinary shares and Sirpa Jalkanen donated 100,000 ordinary shares.
The purpose of the Foundation is to promote and support high-quality medical research in Finland, and the donors want to support the realization of the Foundation's purpose with this donation. The Foundation is independent of Markku and Sirpa Jalkanen. Following receipt of the donation, the Foundation will be interested in 500,000 ordinary shares in the Company, representing approximately 0.45 per cent. of the total voting rights in the Company. In addition, on 3 June 2025, Markku and Sirpa Jalkanen have sold in aggregate 300,000 ordinary shares in the Company. Markku Jalkanen sold 200,000 ordinary shares and Sirpa Jalkanen sold 100,000 ordinary shares.
Further details are set out in the Notification of Dealing Form below.
| Director/PCA | Holding prior to sale/disposal | Number of ordinary shares sold / disposed | Resultant interest in ordinary shares in the Company | Resultant percentage of voting rights in the Company |
|---|---|---|---|---|
| Markku Jalkanen | 2,225,266 | 600,000 | 1,625,266 | 1.45% |
| Sirpa Jalkanen | 1,188,168 | 200,000 | 988,168 | 0.88% |
Following the above transactions, the aggregate holdings of Markku and Sirpa Jalkanen amount to 2,613,434 ordinary shares in the Company, representing approximately 2.33 per cent. of the voting rights in the Company.
| a. | Name | Markku Jalkanen Sirpa Jalkanen |
| 2 | Reason for notification | |
| a. | Position/Status | Non-executive Director PCA |
| b. | Initial notification/ Amendment | Initial Notification |
| a. | Name | Faron Pharmaceuticals Ltd. |
| b. | LEI | 7437009H31TO1DC0EB42 |
| a. | Description of the financial instrument, type of instrument Identification Code | Ordinary Shares ISIN: FI4000153309 |
| b. | Nature of the transaction | Disposal of ordinary shares |
| Price(s) per share (p) | Volume(s) | |
| Nil €3.09816 Nil b) €3.0039 | 400,000 200,000 100,000 b) 100,000 | |
| d. | Aggregated information Volume Price | Transaction details (a) (1): Volume 36,773 Unit price: 3.18 EUR (2): Volume 63,227 Unit price: 3.20 EUR (3): Volume 32,006 Unit price: 3.09 EUR (4): Volume 27,875 Unit price: 2.95 EUR (5): Volume 26,594 Unit price: 2.98 EUR (6): Volume 5,000 Unit price: 3.07 EUR (7): Volume 8,525 Unit price: 2.89 EUR Transaction details (b) (1): Volume 32,006 Unit price: 3.09 EUR (2): Volume 27,875 Unit price: 2.95 EUR (3): Volume 26,594 Unit price: 2.98 EUR (4): Volume 5,000 Unit price: 3.06 EUR (5): Volume 8,525 Unit price: 2.89 EUR |
| f. | Place of the transaction | Nasdaq First North Growth Market |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.